Vemurafenib acts as a potent inhibitor of BRAF-mediated cell signaling and proliferation, and has produced improved progression-free and overall survival in previously untreated metastatic melanoma containing BRAF V600E and V600K mutations. Here, BRAF is linked to metastatic melanoma.